We examined 28 patients with idiopathic RBD (iRBD) without manifest neurodegenerative disease to determine diagnostic accuracy of MMAs and olfactory dysfunction in identifying patients with early nigrostriatal degeneration in transcranial sonography (TCS) and 123I-2尾-carbomethoxy-3尾-(4-iodophenyl)-N-(3-fluoropropyl)-nortropane single-photon emission computed tomography (123I-FP-CIT-SPECT).
Sixty-three percent of our participants showed MMAs which were strongly associated with abnormal TCS and 123I-FP-CIT-SPECT findings. The discriminative value in detecting participants with early nigrostriatal degeneration was excellent (area under the receiver operating characteristic [ROC] curve, 0.84 [P 猢?#xA0;.003] for TCS and 0.79 [P 猢?#xA0;.066] for 123I-FP-CIT-SPECT). Olfactory dysfunction was present in 78% of iRBD participants, but it was not linked with neuroimaging abnormalities or MMAs. Olfactory dysfunction did not discriminate participants with early nigrostriatal degeneration (area under the ROC curve, 0.54 [P 猢?#xA0;.747] for TCS and 0.31 [P 猢?#xA0;.225] for 123I-FP-CIT-SPECT). Early RBD manifestation but no demographic (e.g., age, gender) or clinical characteristics of RBD (e.g., duration, severity of RBD) were associated with neuroimaging abnormalities in TCS and 123I-FP-CIT-SPECT.
Unlike olfactory dysfunction, MMAs discriminate patients with early nigrostriatal degeneration in iRBD. Early RBD manifestation seems to be an additional risk factor which aggravates neurodegenerative risk.